We show GPX4 inhibition by RSL3 to tumorselectively induce extensive ferroptosis in wild-type and mutant p53-expressing MM cells while sparing primary cells of the skin, implying ferroptosis induction to be a viable alternative treatment option for MM irrespective of the intrinsic p53 mutation status. The gene discussed is TP53; the disease is Miyoshi myopathy.